• The new compound is being developed for the treatment of Parkinson's disease.
• The new compound will be administered to humans for the first time in this trial.
• The trial consists of 3 parts: part 1a, part 1b and part 2. You can only participate once.
  • In part 1b and part 2, the compound is administered multiple times as capsules via the mouth.
• In part 1a and part 2 of the trial, your heart rate will constantly be monitored at certain times for 24 or 48 hours. For this you will have stickers (electrodes) on your chest that are attached to a device. If you are connected to this device, you cannot shower, and you must behave as calmly as possible. Occasionally you will even have to lie still for 15 minutes without moving, talking, or sleeping. You will also not be able to listen to music, watch TV or use a laptop or telephone then.

• You are a healthy male or female.
• Part 1b and part 2: You are at least 18 and at most 64 years old.
• Your weight is at least 50 kg and your Body Mass Index (BMI) is at least 18.5 and at most 29.5 kg/m2. 
• Both non-smokers and light smokers or occasional smokers are allowed to participate in this clinical trial (at most 5 cigarettes per day). During your stay in our research facility you are not allowed to smoke.

Note:

• You cannot participate in the trial if you have participated in another clinical trial in the 90 days prior to the first compound administration in this clinical trial (counting from the follow-up visit). This may be longer for certain trials, please contact us for further information.
• To determine if you are suitable to participate in this trial, you will undergo a medical screening. Depending on availability, this can be performed in Groningen or in Utrecht.

• As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:
  • You are using hormonal contraception (for example the contraceptive pill or intra-uterine device containing hormones) in combination with a condom;
  • You are using a copper intra-uterine device in combination with a condom;
  • You have passed the menopause (no periods for at least 12 months);
  • You have been sterilized or your male partner has been sterilized;
  • You are not sexually active according to your lifestyle;
  • You are only sexually active with a partner of the same sex.
• As a male you can only participate if you meet one of the following conditions:
  • You are using a condom during intercourse with a fertile female partner;
  • You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
  • You are not sexually active according to your lifestyle;
  • You are only sexually active with a partner of the same sex.

• Part 1b: The trial consists of 2 periods during each of which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 5 days (4 nights). Each period is followed by 2 short visits. The follow-up will take place during the final short visit.

• Part 2: The trial consists of 1 period during which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 15 days (14 nights), followed by 1 short visit. The follow-up visit will take place 1 – 5 days after the short visit.

Note: You must be available for all dates to be able to participate in this clinical trial.